Osmotica Pharmaceuticals (NASDAQ: OSMT) is a fully integrated biopharmaceutical company headquartered in Dublin, Ireland. The company focuses on women’s health, neurology and generic drug formulations.
Osmotica Pharmaceuticals (NASDAQ: OSMT) 36.7% Change
At press time, OSMT was up 1.04 after remaining flat for much of the week. The stock nearly reached $5.00 after the announcement of a major acquisition. The stock, however, fell slightly where it currently sits around 3.88. Year-to-date, OSMT has remained in the nearly $5.00 to just under $3.00 range.
Why is OSMT Moving?
OSMT stock recently saw massive gains after it announced the purchase of Alora Pharma out of Metro Atlanta for $110 million. With the purchase including a manufacturing facility, Osmotica is positioning itself to grow in the immediate future.
Where to Buy Osmotica Pharmaceuticals Stock
When you are ready to buy OSMT stock, use this list of preferred brokers to get the best results, quality information and impeccable customer support.
Stay Ahead of the Game on OSMT
When you use Benzinga Pro, you can stay ahead of the game on any stock, including OSMT. You can see real-time and historical information for any company, track stocks and make wise decisions to diversify your portfolio and increase profits.
Data for Osmotica Pharmaceuticals as of June 25, 2021
Summary of Osmotica Pharmaceuticals as of June 25, 2021:
Price Change: $2.84 to $3.88
52 Week Low: $2.74
52 Week High: $9.67
Market Cap: $242.1M
Significant Dates for Osmotica Pharmaceuticals:
Next Earnings Date: 8/10/21
Last Earnings Date: 5/13/21
Ex-Dividend Date: No upcoming dividends
Dividend Payment Date: No upcoming dividends
Technical Data of Osmotica Pharmaceuticals as of June 25 2021:
RSI: 77.04 ⮕ Neutral
MACD: Signal Line Buy Over MACD (0.03) ⮕ Bearish
Bollinger Bands: Price $3.88, 20-Day SMA $2.94, Lower Band $2.78, Upper Band $3.10 ⮕ Neutral
See more from Benzinga
Click here for options trades from Benzinga
Best Stock of the Day: Marin Software Inc. (MRIN)
Want to Buy Vinco Ventures (BBIG) Stock? See This First.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.